[HTML][HTML] From emergence to endemicity: a comprehensive review of COVID-19

R Naik, S Avula, SK Palleti, J Gummadi… - Cureus, 2023 - ncbi.nlm.nih.gov
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), later renamed coronavirus
disease 2019 (COVID-19), was first identified in Wuhan, China, in early December 2019 …

COVID‐19 associated mucormycosis surge: A review on multi‐pathway mechanisms

M Pourazizi, A Hakamifard, A Peyman… - Parasite …, 2024 - Wiley Online Library
Mucormycosis is a fungal infection caused by moulds from the Mucorales order. Concerns
have been mounting due to the alarming increase in severe morbidity and mortality …

[HTML][HTML] Risk of COVID-19 hospitalization in people living with HIV and HIV-negative individuals and the role of COVID-19 vaccination: A retrospective cohort study

JH Puyat, A Fowokan, J Wilton, NZ Janjua… - International Journal of …, 2023 - Elsevier
Objective To examine the risk of hospitalization within 14 days of COVID-19 diagnosis
among people living with HIV (PLWH) and HIV-negative individuals who had laboratory …

Response Rate of the Third and Fourth Doses of the BNT162b2 Vaccine Administered to Cancer Patients Undergoing Active Anti-Neoplastic Treatments

A Agbarya, I Sarel, T Ziv-Baran, O Schwartz… - Diseases, 2023 - mdpi.com
The BNT162b2 vaccine is globally used for preventing morbidity and mortality related to
COVID-19. Cancer patients have had priority for receiving the vaccine due to their …

Adjustment of Immunosuppressants to Facilitate Anti-COVID-19 Antibody Production after mRNA Vaccination in Liver Transplant Recipients

WC Lee, HC Hung, JC Lee, CG Huang, PW Huang… - Viruses, 2023 - mdpi.com
Liver transplant recipients are immunocompromised and have low immunogenicity to
produce antibodies in anti-COVID-19 vaccination. Whether immunosuppressant adjustment …

Protective SARS-CoV-2 Antibody Response in Children With Inflammatory Bowel Disease

L Bosa, C Di Chiara, P Gaio, C Cosma… - Frontiers in …, 2022 - frontiersin.org
Background To date, there's no evidence of an increased risk of SARS-CoV-2 infection or
more severe COVID-19 in patients with inflammatory bowel disease (IBD). However …

COVID-19: From Emergence to Endemicity-A Comprehensive Review

R Naik, S Avula, SK Palleti, J Gummadi… - 2023 - preprints.org
Abstract Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), later renamed
Coronavirus Disease 2019 (COVID-19) was first identified in Wuhan, China, in early …

Managing patients who are immunocompromised during the COVID-19 pandemic

RL Pullen Jr - Nursing2023, 2022 - journals.lww.com
The COVID-19 pandemic has caused distinct challenges for immunocompromised
populations, including disease and social management. This article presents strategies to …

Response Rate to the 3rd and 4th Doses of BNT162b2 Vaccine in Cancer Patients Administered with Active Anti-Neoplastic Treatments

A Agbarya, I Sarel, T Ziv-Baran, O Schwartz… - 2023 - preprints.org
The BNT162b2 vaccine is globally used for preventing morbidity and mortality related to
COVID-19. Cancer patients have had priority for receiving the vaccine due to their …

Precision medicine in pediatric inflammatory bowel disease: an omics and non-omics data-driven patient-centered translational research approach

L Bosa - 2023 - research.unipd.it
Background: Inflammatory bowel disease (IBD) is a spectrum of multifactorial disorders
characterized by dysregulated gut immune response to environmental factors in genetically …